Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Novartis
Kivu Bioscience Inc.
ViroMissile, Inc.
Angiex, Inc.
MacroGenics
Avacta Life Sciences Ltd
University of Southern California
National Institutes of Health Clinical Center (CC)
Actym Therapeutics, Inc.
M.D. Anderson Cancer Center
Eli Lilly and Company
GONGCHU Biotechnology Co., Ltd
Jonsson Comprehensive Cancer Center
Eli Lilly and Company
Baxter Healthcare Corporation
German Cancer Research Center
Shanghai PerHum Therapeutics Co., Ltd.
Prelude Therapeutics
DNAtrix, Inc.
National Cancer Institute (NCI)
Corvus Pharmaceuticals, Inc.
Prelude Therapeutics
Pfizer
Emory University
Pfizer
Prelude Therapeutics
Quadriga Biosciences, Inc.
Genzada Pharmaceuticals USA, Inc.
Ludwig Institute for Cancer Research
Philogen S.p.A.
MacroGenics
Seagen Inc.
Celgene
National Institutes of Health Clinical Center (CC)
OPKO Health, Inc.
Virginia Commonwealth University
Pfizer
University Health Network, Toronto
Corcept Therapeutics
Masonic Cancer Center, University of Minnesota
Masonic Cancer Center, University of Minnesota
Masonic Cancer Center, University of Minnesota
Masonic Cancer Center, University of Minnesota
GlaxoSmithKline
Peter MacCallum Cancer Centre, Australia
National Institutes of Health Clinical Center (CC)
University of Louisville
Shenzhen Second People's Hospital
Altor BioScience